Breakthrough cancer therapy stops tumor growth without harming healthy cells
Scientists discovered compounds that block the interaction between the oncogenic RAS protein and PI3K, effectively stopping tumor growth in mouse models of lung and breast cancer while sparing normal cells, and moved the therapy into a first‑human clinical trial for safety and efficacy.
The study reports that small‑molecule inhibitors targeting the RAS‑PI3K interaction can halt tumor growth in mice bearing lung and breast cancer tumors, with no significant side effects such as hyperglycemia. These compounds preserve normal PI3K functions while blocking oncogenic signaling and are now being tested in a first‑in‑human phase I trial for safety and tolerability in patients with RAS and HER2 mutations.
This therapy offers a mechanism to selectively interrupt key oncogenic pathways without impacting normal cellular functions, potentially improving efficacy and reducing toxicity across a broad spectrum of cancers driven by RAS and related signaling.
Bizonyítékszint: Számítógépes vagy elméleti. Modellből vagy adatbányászatból származó jel.